Clinical Trials Directory

Trials / Terminated

TerminatedNCT02581384

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
5 (actual)
Sponsor
Dana-Farber Cancer Institute · Academic / Other
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid). SBRT is a form of targeted radiotherapy that can treat very small tumors using a few large doses.

Detailed description

This research study is a Pilot Study, also known as a Phase I-II study, which means it is the first time investigators are examining this study intervention for patients with lung recurrence of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, nonrhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid). This study tests the most appropriate dose, safety and efficacy of SBRT for the treatment of lung recurrence of these cancers in children. Standard radiotherapy is typically used to treat Ewing sarcoma and is used to treat lung recurrence. SBRT is being used to treat adults with small inoperable lung cancers; in such cases, SBRT has been shown to be effective and well-tolerated. SBRT is also used to treat bone metastases in adults and children.

Conditions

Interventions

TypeNameDescription
RADIATIONStereotactic Body Radiotherapy (SBRT)

Timeline

Start date
2017-01-01
Primary completion
2020-08-01
Completion
2020-08-01
First posted
2015-10-21
Last updated
2021-04-30
Results posted
2021-04-30

Locations

3 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02581384. Inclusion in this directory is not an endorsement.